Filing Details

Accession Number:
0000950170-24-075071
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-06-18 17:58:48
Reporting Period:
2024-06-14
Accepted Time:
2024-06-18 17:58:48
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1595097 Corbus Pharmaceuticals Holdings Inc. CRBP Pharmaceutical Preparations (2834) 464348039
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1626003 Yuval Cohen C/O Corbus Pharmaceuticals Holdings, Inc
500 River Ridge Drive
Norwood MA 02062
Chief Executive Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.0001 Per Share Acquisiton 2024-06-14 16,830 $14.10 101,230 No 4 M Direct
Common Stock, Par Value $0.0001 Per Share Disposition 2024-06-14 16,830 $50.17 84,400 No 4 S Direct
Common Stock, Par Value $0.0001 Per Share Acquisiton 2024-06-14 12,487 $4.26 96,887 No 4 M Direct
Common Stock, Par Value $0.0001 Per Share Disposition 2024-06-14 12,487 $50.17 84,400 No 4 S Direct
Common Stock, Par Value $0.0001 Per Share Acquisiton 2024-06-17 9,333 $30.00 93,733 No 4 M Direct
Common Stock, Par Value $0.0001 Per Share Disposition 2024-06-17 9,333 $46.02 84,400 No 4 S Direct
Common Stock, Par Value $0.0001 Per Share Acquisiton 2024-06-17 1,770 $4.26 86,170 No 4 M Direct
Common Stock, Par Value $0.0001 Per Share Disposition 2024-06-17 1,770 $46.02 84,400 No 4 S Direct
Common Stock, Par Value $0.0001 Per Share Acquisiton 2024-06-18 11,667 $30.00 96,067 No 4 M Direct
Common Stock, Par Value $0.0001 Per Share Disposition 2024-06-18 11,667 $42.24 84,400 No 4 S Direct
Common Stock, Par Value $0.0001 Per Share Acquisiton 2024-06-18 1,770 $14.10 86,170 No 4 M Direct
Common Stock, Par Value $0.0001 Per Share Disposition 2024-06-18 1,770 $42.24 84,400 No 4 S Direct
Common Stock, Par Value $0.0001 Per Share Acquisiton 2024-06-18 2,322 $4.26 86,722 No 4 M Direct
Common Stock, Par Value $0.0001 Per Share Disposition 2024-06-18 2,322 $42.24 84,400 No 4 S Direct
Common Stock, Par Value $0.0001 Per Share Disposition 2024-06-18 7,179 $42.24 77,221 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Options to purchase common stock Disposition 2024-06-14 16,830 $0.00 16,830 $14.10
Common Stock Options to purchase common stock Disposition 2024-06-14 12,487 $0.00 12,487 $4.26
Common Stock Options to purchase common stock Disposition 2024-06-17 9,333 $0.00 9,333 $30.00
Common Stock Options to purchase common stock Disposition 2024-06-17 1,770 $0.00 1,770 $4.26
Common Stock Options to purchase common stock Disposition 2024-06-18 11,667 $0.00 11,667 $30.00
Common Stock Options to purchase common stock Disposition 2024-06-18 1,770 $0.00 1,770 $14.10
Common Stock Options to purchase common stock Disposition 2024-06-18 2,322 $0.00 2,322 $4.26
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
32,827 2023-02-01 2032-02-01 No 4 M Direct
53,831 2024-02-13 2033-02-13 No 4 M Direct
11,667 2024-10-22 No 4 M Direct
52,061 2024-02-13 2033-02-13 No 4 M Direct
0 2024-10-22 No 4 M Direct
31,057 2023-02-01 2032-02-01 No 4 M Direct
49,739 2024-02-13 2033-02-13 No 4 M Direct
Footnotes
  1. This amount includes 73,947 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025.
  2. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024.
  3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.27 to $52.23 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
  4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.0 to $49.38 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
  5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.75 to $43.69 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
  6. The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 1, 2023, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2023.
  7. The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 13, 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024.
  8. The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested.